Increased autophagy in ephrinB2 deficient osteocytes is associated with hypermineralized, brittle bones

Preprint OPEN
Crimeen-Irwin, Blessing; Sims, Natalie; Martin, T; Oakhill, Jonathan; Smyth, Gordon; Tobin, Mark; Petibois, Cyril; Bambery, Keith; Ikegame, Mika; Hu, Yifang; Forwood, Mark; Nguyen, Huynh; Ansari, Niloufar; Dite, Toby; Vrahnas, Christina;
(2018)

Mineralized bone forms when collagen-containing osteoid accrues hydroxyapatite crystals. This process has two phases: a rapid initiation (primary mineralization), followed by slower accrual of mineral (secondary mineralization) that continues until that portion of bone ... View more
  • References (30)
    30 references, page 1 of 3

    1 2 3 4 5 6 7 8 9 10 11 12 13 14 Buenzli, P. R. & Sims, N. A. Quantifying the osteocyte network in the human skeleton. Bone 75, 144-150, doi:10.1016/j.bone.2015.02.016 (2015).

    Schaffler, M. B., Cheung, W. Y., Majeska, R. & Kennedy, O. Osteocytes: master orchestrators of bone. Calcified tissue international 94, 5-24, doi:10.1007/s00223-013-9790-y (2014).

    Walker, E. C. et al. Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. J Clin Invest 120, 582-592, doi:10.1172/JCI40568 (2010).

    Poole, K. E. et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19, 1842-1844, doi:10.1096/fj.05-4221fje (2005).

    Houston, B., Stewart, A. J. & Farquharson, C. PHOSPHO1-A novel phosphatase specifically expressed at sites of mineralisation in bone and cartilage. Bone 34, 629-637, doi:10.1016/j.bone.2003.12.023 (2004).

    Ling, Y. et al. DMP1 depletion decreases bone mineralization in vivo: an FTIR imaging analysis. J Bone Miner Res 20, 2169-2177, doi:10.1359/JBMR.050815 (2005).

    Gowen, L. C. et al. Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem 278, 1998-2007, doi:10.1074/jbc.M203250200 (2003).

    Miao, D. et al. Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1- 34. J Clin Invest 115, 2402-2411 (2005).

    Ansari, N. et al. Autocrine and Paracrine Regulation of the Murine Skeleton by Osteocyte-Derived Parathyroid Hormone-Related Protein. J Bone Miner Res, doi:10.1002/jbmr.3291 (2017).

    Lindsay, R. et al. Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 22, 495-502, doi:10.1359/jbmr.070104 (2007).

  • Related Research Results (1)
  • Metrics
    No metrics available
Share - Bookmark